Notably, liposome surface modification technology can give it an active targeting ability, for example, by integrating transferrin receptor ligands, the drug delivery system can specifically recognize the overexpression of transferrin receptors on the surface of tumor cells, so as to achieve precise drug accumulation in the TME [122]. The gene discussed is TFRC; the disease is neoplasm.